Bolt Biotherapeutics (NASDAQ:BOLT) Releases Earnings Results, Misses Estimates By $0.04 EPS

Bolt Biotherapeutics (NASDAQ:BOLT) posted its quarterly earnings results on Tuesday. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.04), Zacks reports. The business had revenue of $1.14 million during the quarter, compared to analyst estimates of $1.02 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 64.49%.

Bolt Biotherapeutics Stock Performance

Shares of BOLT traded up $0.01 during mid-day trading on Thursday, reaching $0.62. 30,804 shares of the company’s stock traded hands, compared to its average volume of 164,968. Bolt Biotherapeutics has a 12 month low of $0.55 and a 12 month high of $1.56. The stock has a market capitalization of $23.82 million, a P/E ratio of -0.36 and a beta of 0.92. The business’s 50-day moving average price is $0.64 and its 200-day moving average price is $0.74. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.28 and a current ratio of 4.28.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “neutral” rating on shares of Bolt Biotherapeutics in a research note on Wednesday. Five research analysts have rated the stock with a hold rating, According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $3.50.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.